vs

Side-by-side financial comparison of Cineverse Corp. (CNVS) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $16.3M, roughly 1.2× Cineverse Corp.). Cineverse Corp. runs the higher net margin — -5.4% vs -177.4%, a 172.0% gap on every dollar of revenue. On growth, STANDARD BIOTOOLS INC. posted the faster year-over-year revenue change (-11.5% vs -60.0%). Over the past eight quarters, Cineverse Corp.'s revenue compounded faster (28.5% CAGR vs -12.2%).

Cineverse Corp. is an American entertainment company headquartered in Los Angeles, California. Cineverse’s businesses encompass digital cinema, streaming channels, content marketing, and distribution.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

CNVS vs LAB — Head-to-Head

Bigger by revenue
LAB
LAB
1.2× larger
LAB
$19.6M
$16.3M
CNVS
Growing faster (revenue YoY)
LAB
LAB
+48.6% gap
LAB
-11.5%
-60.0%
CNVS
Higher net margin
CNVS
CNVS
172.0% more per $
CNVS
-5.4%
-177.4%
LAB
Faster 2-yr revenue CAGR
CNVS
CNVS
Annualised
CNVS
28.5%
-12.2%
LAB

Income Statement — Q3 FY2026 vs Q3 FY2025

Metric
CNVS
CNVS
LAB
LAB
Revenue
$16.3M
$19.6M
Net Profit
$-875.0K
$-34.7M
Gross Margin
48.5%
Operating Margin
-4.0%
-168.5%
Net Margin
-5.4%
-177.4%
Revenue YoY
-60.0%
-11.5%
Net Profit YoY
-112.2%
-28.8%
EPS (diluted)
$-0.05
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CNVS
CNVS
LAB
LAB
Q4 25
$16.3M
Q3 25
$12.4M
$19.6M
Q2 25
$11.1M
$21.8M
Q1 25
$15.6M
$40.8M
Q4 24
$40.7M
Q3 24
$12.7M
$22.1M
Q2 24
$9.1M
$22.5M
Q1 24
$9.9M
$45.5M
Net Profit
CNVS
CNVS
LAB
LAB
Q4 25
$-875.0K
Q3 25
$-5.5M
$-34.7M
Q2 25
$-3.5M
$-33.5M
Q1 25
$856.0K
$-26.0M
Q4 24
$7.2M
Q3 24
$-1.2M
$-26.9M
Q2 24
$-3.0M
$-45.7M
Q1 24
$-14.7M
$-32.2M
Gross Margin
CNVS
CNVS
LAB
LAB
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q4 24
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Operating Margin
CNVS
CNVS
LAB
LAB
Q4 25
-4.0%
Q3 25
-43.8%
-168.5%
Q2 25
-33.3%
-118.1%
Q1 25
13.7%
-80.8%
Q4 24
23.2%
Q3 24
-6.8%
-120.9%
Q2 24
-30.4%
-134.5%
Q1 24
-141.9%
-132.2%
Net Margin
CNVS
CNVS
LAB
LAB
Q4 25
-5.4%
Q3 25
-44.9%
-177.4%
Q2 25
-31.6%
-153.7%
Q1 25
5.5%
-63.8%
Q4 24
17.6%
Q3 24
-9.4%
-122.0%
Q2 24
-33.4%
-203.3%
Q1 24
-148.8%
-70.6%
EPS (diluted)
CNVS
CNVS
LAB
LAB
Q4 25
$-0.05
Q3 25
$-0.31
$-0.09
Q2 25
$-0.21
$-0.09
Q1 25
$0.11
$-0.07
Q4 24
$0.34
Q3 24
$-0.09
$-0.07
Q2 24
$-0.20
$-0.12
Q1 24
$-1.15
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CNVS
CNVS
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$2.5M
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$38.6M
$399.7M
Total Assets
$68.6M
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CNVS
CNVS
LAB
LAB
Q4 25
$2.5M
Q3 25
$2.3M
$129.4M
Q2 25
$2.0M
$158.6M
Q1 25
$13.9M
$150.9M
Q4 24
$6.1M
Q3 24
$2.4M
$210.6M
Q2 24
$4.0M
$269.8M
Q1 24
$5.2M
$287.1M
Total Debt
CNVS
CNVS
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
CNVS
CNVS
LAB
LAB
Q4 25
$38.6M
Q3 25
$38.0M
$399.7M
Q2 25
$37.1M
$424.5M
Q1 25
$38.8M
$454.6M
Q4 24
$37.4M
Q3 24
$29.8M
$489.3M
Q2 24
$30.5M
$510.3M
Q1 24
$33.3M
$577.3M
Total Assets
CNVS
CNVS
LAB
LAB
Q4 25
$68.6M
Q3 25
$61.9M
$539.6M
Q2 25
$61.5M
$557.0M
Q1 25
$72.5M
$579.6M
Q4 24
$80.5M
Q3 24
$60.6M
$681.5M
Q2 24
$62.3M
$708.7M
Q1 24
$64.4M
$777.7M
Debt / Equity
CNVS
CNVS
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CNVS
CNVS
LAB
LAB
Operating Cash FlowLast quarter
$-1.6M
$-22.2M
Free Cash FlowOCF − Capex
$-23.1M
FCF MarginFCF / Revenue
-118.1%
Capex IntensityCapex / Revenue
4.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CNVS
CNVS
LAB
LAB
Q4 25
$-1.6M
Q3 25
$-7.2M
$-22.2M
Q2 25
$-14.5M
$-20.7M
Q1 25
$12.5M
$-30.3M
Q4 24
$7.4M
Q3 24
$-85.0K
$-27.9M
Q2 24
$-2.3M
$-39.0M
Q1 24
$-1.3M
$-62.5M
Free Cash Flow
CNVS
CNVS
LAB
LAB
Q4 25
Q3 25
$-23.1M
Q2 25
$-22.6M
Q1 25
$-35.3M
Q4 24
Q3 24
$-30.1M
Q2 24
$-41.0M
Q1 24
$-63.3M
FCF Margin
CNVS
CNVS
LAB
LAB
Q4 25
Q3 25
-118.1%
Q2 25
-103.6%
Q1 25
-86.6%
Q4 24
Q3 24
-136.4%
Q2 24
-182.2%
Q1 24
-138.9%
Capex Intensity
CNVS
CNVS
LAB
LAB
Q4 25
Q3 25
4.5%
Q2 25
8.7%
Q1 25
12.4%
Q4 24
Q3 24
10.2%
Q2 24
8.6%
Q1 24
1.7%
Cash Conversion
CNVS
CNVS
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
14.56×
Q4 24
1.03×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CNVS
CNVS

OTT Streamingand Digital$11.5M71%
Base Distribution$3.5M22%
Podcast And Other$1.3M8%

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons